Skip to main content
. Author manuscript; available in PMC: 2022 Jun 22.
Published in final edited form as: Circulation. 2021 Jun 21;143(25):2471–2474. doi: 10.1161/CIRCULATIONAHA.121.054900

Figure 1. Model for discovery and validation of novel drug targets for complex diseases using integrative single-cell non-biased -omics.

Figure 1.

A discovery phase using both human disease and animal model single cell -omics profiling is recommended. Integrative computational methods are applied to cross-species and cross-platform data to identify and prioritize master regulatory and druggable targets of greatest importance in human disease. Experimental functional studies in animal models of disease and in disease-relevant human cells, including gene-manipulation in human induced pluripotent stems cells, can define precise molecular and cellular targets for translation via clinical trials and precision therapeutic strategies. Figure created with BioRender.com.